Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 8/2023

31-03-2023 | Retinoblastoma | REVIEW ARTICLE

The functional role of circular RNAs in the pathogenesis of retinoblastoma: a new potential biomarker and therapeutic target?

Authors: Mohsen Karami Fath, Sasan Pourbagher Benam, Niloofar Kouhi Esfahani, Negar Shahkarami, Shahriyar Shafa, Hossein Bagheri, Seyyed-Ghavam Shafagh, Zahra Payandeh, Ghasem Barati

Published in: Clinical and Translational Oncology | Issue 8/2023

Login to get access

Abstract

Retinoblastoma (RB) is a common cancer in infants and children. It is a curable disease; however, a delayed diagnosis or treatment makes the treatment difficult. Genetic mutations have a central role in the pathogenesis of RB. Genetic materials such as RNAs (coding and non-coding RNAs) are also involved in the progression of the tumor. Circular RNA (circRNA) is the most recently identified RNA and is involved in regulating gene expression mainly through “microRNA sponges”. The dysregulation of circRNAs has been observed in several diseases and tumors. Also, various studies have shown that circRNAs expression is changed in RB tissues. Due to their role in the pathogenesis of the disease, circRNAs might be helpful as a diagnostic or prognostic biomarker in patients with RB. In addition, circRNAs could be a suitable therapeutic target to treat RB in a targeted therapy approach.
Literature
1.
2.
3.
4.
5.
6.
Dimaras H, Khetan V, Halliday W, Orlic M, Prigoda NL, Piovesan B, et al. Loss of RB1 induces non-proliferative retinoma: increasing genomic instability correlates with progression to retinoblastoma. Hum Mol Genet. 2008;17(10):1363–72.CrossRefPubMed
7.
Dimaras H, Kimani K, Dimba EAO, Gronsdahl P, White A, Chan HSL, et al. Retinoblastoma. Lancet. 2012;379(9824):1436–46.CrossRefPubMed
8.
Thériault BL, Dimaras H, Gallie BL, Corson TW. The genomic landscape of retinoblastoma: a review. Clin Exp Ophthalmol. 2014;42(1):33–52.CrossRefPubMed
9.
Zhang J, Benavente CA, McEvoy J, Flores-Otero J, Ding L, Chen X, et al. A novel retinoblastoma therapy from genomic and epigenetic analyses. Nature. 2012;481(7381):329–34.CrossRefPubMedPubMedCentral
10.
Khan M, Walters LL, Li Q, Thomas DG, Miller JML, Zhang Q, et al. Characterization and pharmacologic targeting of EZH2, a fetal retinal protein and epigenetic regulator, in human retinoblastoma. Lab Invest. 2015;95(11):1278–90.CrossRefPubMedPubMedCentral
11.
Golabchi K, Soleimani-Jelodar R, Aghadoost N, Momeni F, Moridikia A, Nahand JS, et al. MicroRNAs in retinoblastoma: potential diagnostic and therapeutic biomarkers. J Cell Physiol. 2018;233(4):3016–23.CrossRefPubMed
12.
13.
14.
15.
Li J, Sun D, Pu W, Wang J, Peng Y. Circular RNAs in cancer: biogenesis, function, and clinical significance. Trends in Cancer. 2020;6(4):319–36.CrossRefPubMed
16.
Kristensen LS, Andersen MS, Stagsted LVW, Ebbesen KK, Hansen TB, Kjems J. The biogenesis, biology and characterization of circular RNAs. Nat Rev Genet. 2019;20(11):675–91.CrossRefPubMed
17.
Ashwal-Fluss R, Meyer M, Pamudurti NR, Ivanov A, Bartok O, Hanan M, et al. circRNA biogenesis competes with pre-mRNA splicing. Mol Cell. 2014;56(1):55–66.CrossRefPubMed
18.
Conn SJ, Pillman KA, Toubia J, Conn VM, Salmanidis M, Phillips CA, et al. The RNA binding protein quaking regulates formation of circRNAs. Cell. 2015;160(6):1125–34.CrossRefPubMed
19.
Ivanov A, Memczak S, Wyler E, Torti F, Porath HT, Orejuela MR, et al. Analysis of intron sequences reveals hallmarks of circular RNA biogenesis in animals. Cell Rep. 2015;10(2):170–7.CrossRefPubMed
20.
21.
22.
Li Z, Huang C, Bao C, Chen L, Lin M, Wang X, et al. Exon-intron circular RNAs regulate transcription in the nucleus. Nat Struct Mol Biol. 2015;22(3):256–64.CrossRefPubMed
23.
Liang D, Tatomer DC, Luo Z, Wu H, Yang L, Chen L-L, et al. The output of protein-coding genes shifts to circular RNAs when the pre-mRNA processing machinery is limiting. Mol Cell. 2017;68(5):940-954.e3.CrossRefPubMedPubMedCentral
24.
Lu Q, Liu T, Feng H, Yang R, Zhao X, Chen W, et al. Circular RNA circSLC8A1 acts as a sponge of miR-130b/miR-494 in suppressing bladder cancer progression via regulating PTEN. Mol Cancer. 2019;18(1):111.CrossRefPubMedPubMedCentral
25.
Abdelmohsen K, Panda AC, Munk R, Grammatikakis I, Dudekula DB, De S, et al. Identification of HuR target circular RNAs uncovers suppression of PABPN1 translation by CircPABPN1. RNA Biol. 2017;14(3):361–9.CrossRefPubMedPubMedCentral
26.
Zhang M, Huang N, Yang X, Luo J, Yan S, Xiao F, et al. A novel protein encoded by the circular form of the SHPRH gene suppresses glioma tumorigenesis. Oncogene. 2018;37(13):1805–14.CrossRefPubMed
27.
Harper KL, McDonnell E, Whitehouse A. CircRNAs: from anonymity to novel regulators of gene expression in cancer (Review). Int J Oncol. 2019;55(6):1183–93.PubMed
28.
Zhu L-P, He Y-J, Hou J-C, Chen X, Zhou S-Y, Yang S-J, et al. The role of circRNAs in cancers. Biosci Rep. 2017;37(5):1–11.CrossRef
29.
Verduci L, Tarcitano E, Strano S, Yarden Y, Blandino G. CircRNAs: role in human diseases and potential use as biomarkers. Cell Death Dis. 2021;12(5):468.CrossRefPubMedPubMedCentral
30.
31.
Sun Z, Zhang A, Hou M, Jiang T. Circular RNA hsa_circ_0000034 promotes the progression of retinoblastoma via sponging microRNA-361-3p. Bioengineered. 2020;11(1):949–57.CrossRefPubMedPubMedCentral
32.
Liu H, Yuan H, Xu D, Chen K, Tan N, Zheng Q. Circular RNA circ_0000034 upregulates STX17 level to promote human retinoblastoma development via inhibiting miR-361-3p. Eur Rev Med Pharmacol Sci. 2020;24(23):12080–92.PubMed
33.
Wang H, Li M, Cui H, Song X, Sha Q. CircDHDDS/miR-361-3p/WNT3A axis promotes the development of retinoblastoma by regulating proliferation, cell cycle, migration, and invasion of retinoblastoma cells. Neurochem Res. 2020;45(11):2691–702.CrossRefPubMed
34.
Jiang Y, Xiao F, Wang L, Wang T, Chen L. Circular RNA has_circ_0000034 accelerates retinoblastoma advancement through the miR-361-3p/ADAM19 axis. Mol Cell Biochem. 2021;476(1):69–80.CrossRefPubMed
35.
Fu C, Wang S, Jin L, Zhang M, Li M. CircTET1 inhibits retinoblastoma progression via targeting miR-492 and miR-494-3p through Wnt/β-catenin signaling pathway. Curr Eye Res. 2021;46(7):978–87.CrossRefPubMed
36.
Lyu J, Wang Y, Zheng Q, Hua P, Zhu X, Li J, et al. Reduction of circular RNA expression associated with human retinoblastoma. Exp Eye Res. 2019;184:278–85.CrossRefPubMed
37.
Chen N-N, Chao D-L, Li X-G. Circular RNA has_circ_0000527 participates in proliferation, invasion and migration of retinoblastoma cells via miR-646/BCL-2 axis. Cell Biochem Funct. 2020;38(8):1036–46.CrossRefPubMed
38.
Zhang L, Wu J, Li Y, Jiang Y, Wang L, Chen Y, et al. Circ_0000527 promotes the progression of retinoblastoma by regulating miR-646/LRP6 axis. Cancer Cell Int. 2020;20(1):1–12.CrossRef
39.
Yu B, Zhao J, Dong Y. Circ_0000527 promotes retinoblastoma progression through modulating miR-98-5p/XIAP pathway. Curr Eye Res. 2021;46(9):1414–23.CrossRefPubMed
40.
Zuo X, Fu C, Xie J, Wang X, Yan Z. Hsa_circ_0000527 downregulation suppresses the development of retinoblastoma by modulating the miR-27a-3p/HDAC9 pathway. Curr Eye Res. 2022;47(1):115–26.CrossRefPubMed
41.
42.
Zheng T, Chen W, Wang X, Cai W, Wu F, Lin C. Circular RNA circ-FAM158A promotes retinoblastoma progression by regulating miR-138–5p/SLC7A5 axis. Exp Eye Res. 2021;211: 108650.CrossRefPubMed
43.
Huang Y, Xue B, Pan J, Shen N. Circ-E2F3 acts as a ceRNA for miR-204-5p to promote proliferation, metastasis and apoptosis inhibition in retinoblastoma by regulating ROCK1 expression. Exp Mol Pathol. 2021;120: 104637.CrossRefPubMed
44.
Zhao W, Wang S, Qin T, Wang W. Circular RNA (circ-0075804) promotes the proliferation of retinoblastoma via combining heterogeneous nuclear ribonucleoprotein K (HNRNPK) to improve the stability of E2F transcription factor 3 E2F3. J Cell Biochem. 2020;121(7):3516–25.CrossRefPubMed
45.
Zhang Y, Dou X, Kong Q, Li Y, Zhou X. Circ_0075804 promotes the malignant behaviors of retinoblastoma cells by binding to miR-138-5p to induce PEG10 expression. Int Ophthalmol. 2022;42(2):509–23.CrossRefPubMed
46.
47.
Xing L, Zhang L, Feng Y, Cui Z, Ding L. Downregulation of circular RNA hsa_circ_0001649 indicates poor prognosis for retinoblastoma and regulates cell proliferation and apoptosis via AKT/mTOR signaling pathway. Biomed Pharmacother. 2018;105:326–33.CrossRefPubMed
48.
Du S, Wang S, Zhang F, Lv Y. SKP2, positively regulated by circ_ODC1/miR-422a axis, promotes the proliferation of retinoblastoma. J Cell Biochem. 2020;121(1):322–31.CrossRefPubMed
49.
Jiang Y, Xiao F, Wang L, Wang T, Chen L. Hsa_circ_0099198 facilitates the progression of retinoblastoma by regulating miR-1287/LRP6 axis. Exp Eye Res. 2021;206: 108529.CrossRefPubMed
50.
Zhang H, Qiu X, Song Z, Lan L, Ren X, Ye B. CircCUL2 suppresses retinoblastoma cells by regulating miR-214-5p/E2F2 Axis. Anticancer Drugs. 2022;33(1):e218–27.CrossRefPubMed
51.
Lv X, Yang H, Zhong H, He L, Wang L. Osthole exhibits an antitumor effect in retinoblastoma through inhibiting the PI3K/AKT/mTOR pathway via regulating the hsa_circ_0007534/miR-214-3p axis. Pharm Biol. 2022;60(1):417–26.CrossRefPubMedPubMedCentral
52.
53.
Ji W, Qiu C, Wang M, Mao N, Wu S, Dai Y. Hsa_circ_0001649: a circular RNA and potential novel biomarker for colorectal cancer. Biochem Biophys Res Commun. 2018;497(1):122–6.CrossRefPubMed
54.
Zhang X, Qiu S, Luo P, Zhou H, Jing W, Liang C, et al. Down-regulation of hsa_circ_0001649 in hepatocellular carcinoma predicts a poor prognosis. Cancer Biomark. 2018;22:135–42.CrossRefPubMed
55.
Xu Y, Yao Y, Zhong X, Leng K, Qin W, Qu L, et al. Downregulated circular RNA hsa_circ_0001649 regulates proliferation, migration and invasion in cholangiocarcinoma cells. Biochem Biophys Res Commun. 2018;496(2):455–61.CrossRefPubMed
56.
Zhao D, Cui Z. MicroRNA-361-3p regulates retinoblastoma cell proliferation and stemness by targeting hedgehog signaling. Exp Ther Med. 2019;17(2):1154–62.PubMed
57.
Yao H, Chen R, Yang Y, Jiang J. LncRNA BBOX1-AS1 aggravates the development of ovarian cancer by sequestering miR-361-3p to augment PODXL expression. Reprod Sci. 2021;28(3):736–44.CrossRefPubMed
58.
Zhang Z, Mou Z, Xu C, Wu S, Dai X, Chen X, et al. Autophagy-associated circular RNA hsa_circ_0007813 modulates human bladder cancer progression via hsa-miR-361-3p/IGF2R regulation. Cell Death Dis. 2021;12(8):778.CrossRefPubMedPubMedCentral
59.
Feng Z-H, Zheng L, Yao T, Tao S-Y, Wei X-A, Zheng Z-Y, et al. EIF4A3-induced circular RNA PRKAR1B promotes osteosarcoma progression by miR-361-3p-mediated induction of FZD4 expression. Cell Death Dis. 2021;12(11):1025.CrossRefPubMedPubMedCentral
60.
Liu B, Sun Y, Tang M, Liang C, Huang C-P, Niu Y, et al. The miR-361-3p increases enzalutamide (Enz) sensitivity via targeting the ARv7 and MKNK2 to better suppress the Enz-resistant prostate cancer. Cell Death Dis. 2020;11(9):807.CrossRefPubMedPubMedCentral
61.
Liu S, Song L, Yao H, Zhang L, Xu D, Li Q, et al. Preserved miR-361-3p expression is an independent prognostic indicator of favorable survival in cervical cancer. Dis Markers. 2018;2018:8949606.CrossRefPubMedPubMedCentral
62.
Xia F, Chen Y, Jiang B, Bai N, Li X. Hsa_circ_0011385 accelerates the progression of thyroid cancer by targeting miR-361-3p. Cancer Cell Int. 2020;20(1):49.CrossRefPubMedPubMedCentral
63.
Chen L, Nan A, Zhang N, Jia Y, Li X, Ling Y, et al. Circular RNA 100146 functions as an oncogene through direct binding to miR-361-3p and miR-615-5p in non-small cell lung cancer. Mol Cancer. 2019;18(1):13.CrossRefPubMedPubMedCentral
64.
Itakura E, Kishi-Itakura C, Mizushima N. The hairpin-type tail-anchored SNARE syntaxin 17 targets to autophagosomes for fusion with endosomes/lysosomes. Cell. 2012;151(6):1256–69.CrossRefPubMed
65.
Uematsu M, Nishimura T, Sakamaki Y, Yamamoto H, Mizushima N. Accumulation of undegraded autophagosomes by expression of dominant-negative STX17 (syntaxin 17) mutants. Autophagy. 2017;13(8):1452–64.CrossRefPubMedPubMedCentral
66.
Huang J, Yang Y, Fang F, Liu K. MALAT1 modulates the autophagy of retinoblastoma cell through miR-124-mediated stx17 regulation. J Cell Biochem. 2018;119(5):3853–63.CrossRefPubMed
67.
68.
Qi B, Newcomer RG, Sang Q-XA. ADAM19/adamalysin 19 structure, function, and role as a putative target in tumors and inflammatory diseases. Curr Pharm Des. 2009;15(20):2336–48.CrossRefPubMed
69.
Finnerty JR, Wang W-X, Hébert SS, Wilfred BR, Mao G, Nelson PT. The miR-15/107 group of microRNA genes: evolutionary biology, cellular functions, and roles in human diseases. J Mol Biol. 2010;402(3):491–509.CrossRefPubMedPubMedCentral
70.
Li W, Liu M, Feng Y, Xu YF, Huang YF, Che JP, et al. Downregulated miR-646 in clear cell renal carcinoma correlated with tumour metastasis by targeting the nin one binding protein (NOB1). Br J Cancer. 2014;111(6):1188–200.CrossRefPubMedPubMedCentral
71.
Zhang P, Tang WM, Zhang H, Li YQ, Peng Y, Wang J, et al. MiR-646 inhibited cell proliferation and EMT-induced metastasis by targeting FOXK1 in gastric cancer. Br J Cancer. 2017;117(4):525–34.CrossRefPubMedPubMedCentral
72.
Ola MS, Nawaz M, Ahsan H. Role of Bcl-2 family proteins and caspases in the regulation of apoptosis. Mol Cell Biochem. 2011;351(1):41–58.CrossRefPubMed
73.
Ashkenazi A, Fairbrother WJ, Leverson JD, Souers AJ. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors. Nat Rev Drug Discov. 2017;16(4):273–84.CrossRefPubMed
74.
75.
Wang ZM, Luo JQ, Xu LY, Zhou HH, Zhang W. Harnessing low-density lipoprotein receptor protein 6 (LRP6) genetic variation and Wnt signaling for innovative diagnostics in complex diseases. Pharmacogenomics J. 2018;18(3):351–8.CrossRefPubMed
76.
Yan G, Li C, Zhao Y, Yue M, Wang L. Downregulation of microRNA-629-5p in colorectal cancer and prevention of the malignant phenotype by direct targeting of low-density lipoprotein receptor-related protein 6. Int J Mol Med. 2019;44(3):1139–50 (Retraction in /10.3892/ijmm.2021.5057).PubMed
77.
Kong W, Yang L, Li P, Kong Q, Wang H, Han G, et al. MiR-381-3p inhibits proliferation, migration and invasion by targeting LRP6 in papillary thyroid carcinoma. Eur Rev Med Pharmacol Sci. 2018;22(12):3804–11.PubMed
78.
Wang J, Wang X, Li Z, Liu H, Teng Y. Retracted: MicroRNA-183 suppresses retinoblastoma cell growth, invasion and migration by targeting LRP6. FEBS J. 2014;281(5):1355–65.CrossRefPubMed
79.
Miko E, Margitai Z, Czimmerer Z, Várkonyi I, Dezső B, Lányi Á, et al. miR-126 inhibits proliferation of small cell lung cancer cells by targeting SLC7A5. FEBS Lett. 2011;585(8):1191–6.CrossRefPubMed
80.
Wang J, Fei X, Wu W, Chen X, Su L, Zhu Z, et al. SLC7A5 functions as a downstream target modulated by CRKL in metastasis process of gastric cancer SGC-7901 cells. PLoS ONE. 2016;11(11): e0166147.CrossRefPubMedPubMedCentral
81.
He T-G, Xiao Z-Y, Xing Y-Q, Yang H-J, Qiu H, Chen J-B. Tumor suppressor miR-184 enhances chemosensitivity by directly inhibiting SLC7A5 in retinoblastoma. Front Oncol. 2019;9:1163.CrossRefPubMedPubMedCentral
82.
Nicklin P, Bergman P, Zhang B, Triantafellow E, Wang H, Nyfeler B, et al. Bidirectional transport of amino acids regulates mTOR and autophagy. Cell. 2009;136(3):521–34.CrossRefPubMedPubMedCentral
83.
Wang Z, Yao Y, Zheng F, Guan Z, Zhang L, Dong N, et al. Mir-138-5p acts as a tumor suppressor by targeting pyruvate dehydrogenase kinase 1 in human retinoblastoma. Eur Rev Med Pharmacol Sci. 2017;21(24):5624–9.PubMed
84.
Wang X, Zhao Y, Cao W, Wang C, Sun B, Chen J, et al. miR-138-5p acts as a tumor suppressor by targeting hTERT in human colorectal cancer. Int J Clin Exp Pathol. 2017;10(12):11516–25.PubMedPubMedCentral
85.
Zhao C, Ling X, Li X, Hou X, Zhao D. MicroRNA-138-5p inhibits cell migration, invasion and EMT in breast cancer by directly targeting RHBDD1. Breast Cancer. 2019;26(6):817–25.CrossRefPubMed
86.
Schimmer AD, Dalili S, Batey RA, Riedl SJ. Targeting XIAP for the treatment of malignancy. Cell Death Differ. 2006;13(2):179–88.CrossRefPubMed
87.
Lapierre M, Linares A, Dalvai M, Duraffourd C, Bonnet S, Boulahtouf A, et al. Histone deacetylase 9 regulates breast cancer cell proliferation and the response to histone deacetylase inhibitors. Oncotarget. 2016;7(15):19693–708.CrossRefPubMedPubMedCentral
88.
Ma Z, Liu D, Di S, Zhang Z, Li W, Zhang J, et al. Histone deacetylase 9 downregulation decreases tumor growth and promotes apoptosis in non-small cell lung cancer after melatonin treatment. J Pineal Res. 2019;67(2): e12587.CrossRefPubMed
89.
Maliekal TT, Antony M-L, Nair A, Paulmurugan R, Karunagaran D. Loss of expression, and mutations of Smad 2 and Smad 4 in human cervical cancer. Oncogene. 2003;22(31):4889–97.CrossRefPubMed
90.
Kim J, Kong J, Chang H, Kim H, Kim A. EGF induces epithelial-mesenchymal transition through phospho-Smad2/3-Snail signaling pathway in breast cancer cells. Oncotarget. 2016;7(51):85021–32.CrossRefPubMedPubMedCentral
91.
Zhang L, Zhu Z, Yan H, Wang W, Wu Z, Zhang F, et al. Creatine promotes cancer metastasis through activation of Smad2/3. Cell Metab. 2021;33(6):1111-1123.e4.CrossRefPubMed
92.
Duan H, Yan Z, Chen W, Wu Y, Han J, Guo H, et al. TET1 inhibits EMT of ovarian cancer cells through activating Wnt/β-catenin signaling inhibitors DKK1 and SFRP2. Gynecol Oncol. 2017;147(2):408–17.CrossRefPubMed
93.
94.
Tian Y, Pan F, Sun X, Gan M, Lin A, Zhang D, et al. Association of TET1 expression with colorectal cancer progression. Scand J Gastroenterol. 2017;52(3):312–20.CrossRefPubMed
95.
Shen F, Mo M-H, Chen L, An S, Tan X, Fu Y, et al. MicroRNA-21 down-regulates Rb1 expression by targeting PDCD4 in retinoblastoma. J Cancer. 2014;5(9):804–12.CrossRefPubMedPubMedCentral
96.
Xu L, Long H, Zhou B, Jiang H, Cai M. CircMKLN1 suppresses the progression of human retinoblastoma by modulation of miR-425-5p/PDCD4 axis. Curr Eye Res. 2021;46(11):1751–61.CrossRefPubMed
97.
Göke R, Barth P, Schmidt A, Samans B, Lankat-Buttgereit B. Programmed cell death protein 4 suppresses CDK1/cdc2 via induction of p21Waf1/Cip1. Am J Physiol Cell Physiol. 2004;287(6):C1541–6.CrossRefPubMed
98.
Zheng S, Zhong Y-F, Tan D-M, Xu Y, Chen H-X, Wang D. miR-183-5p enhances the radioresistance of colorectal cancer by directly targeting ATG5. J Biosci. 2019;44(4):92.CrossRefPubMed
99.
Ma Y, Liang AJ, Fan Y-P, Huang Y-R, Zhao X-M, Sun Y, et al. Dysregulation and functional roles of miR-183-96-182 cluster in cancer cell proliferation, invasion and metastasis. Oncotarget. 2016;7(27):42805–25.CrossRefPubMedPubMedCentral
100.
101.
Shen F, Cai W-S, Feng Z, Li J-L, Chen J-W, Cao J, et al. MiR-492 contributes to cell proliferation and cell cycle of human breast cancer cells by suppressing SOX7 expression. Tumor Biology. 2015;36(3):1913–21.CrossRefPubMed
102.
Jiang J, Zhang Y, Yu C, Li Z, Pan Y, Sun C. MicroRNA-492 expression promotes the progression of hepatic cancer by targeting PTEN. Cancer Cell Int. 2014;14(1):95.CrossRefPubMedPubMedCentral
103.
Shi L, Liang M, Li F, Li T, Lai D, Xie Q, et al. MiR-492 exerts tumor-promoting function in prostate cancer through repressing SOCS2 expression. Eur Rev Med Pharmacol Sci. 2019;23(3):992–1001.PubMed
104.
Wang K, Lü H, Qu H, Xie Q, Sun T, Gan O, et al. miR-492 promotes cancer progression by targeting GJB4 and is a novel biomarker for bladder cancer. Onco Targets Ther. 2019;12:11453–64.CrossRefPubMedPubMedCentral
105.
106.
Vuaroqueaux V, Urban P, Labuhn M, Delorenzi M, Wirapati P, Benz CC, et al. Low E2F1 transcript levels are a strong determinant of favorable breast cancer outcome. Breast cancer research : BCR. 2007;9(3):R33.CrossRefPubMedPubMedCentral
107.
Justenhoven C, Pierl CB, Haas S, Fischer HP, Hamann U, Baisch C, et al. Polymorphic loci of E2F2, CCND1 and CCND3 are associated with HER2 status of breast tumors. Int J Cancer. 2009;124(9):2077–81.CrossRefPubMed
108.
Feo F, De Miglio MR, Simile MM, Muroni MR, Calvisi DF, Frau M, et al. Hepatocellular carcinoma as a complex polygenic disease. Interpretive analysis of recent developments on genetic predisposition. Biochem Biophys Acta. 2006;1765(2):126–47.PubMed
109.
Zhang J, Xing L, Xu H, Wang K, She J, Shi F, et al. miR-204-5p suppress lymph node metastasis via regulating CXCL12 and CXCR4 in gastric cancer. J Cancer. 2020;11(11):3199–206.CrossRefPubMedPubMedCentral
110.
Shen J, Xiong J, Shao X, Cheng H, Fang X, Sun Y, et al. Knockdown of the long noncoding RNA XIST suppresses glioma progression by upregulating miR-204-5p. J Cancer. 2020;11(15):4550–9.CrossRefPubMedPubMedCentral
111.
Yao S, Yin Y, Jin G, Li D, Li M, Hu Y, et al. Exosome-mediated delivery of miR-204-5p inhibits tumor growth and chemoresistance. Cancer Med. 2020;9(16):5989–98.CrossRefPubMedPubMedCentral
112.
Wang Y, Wang N, Zeng X, Sun J, Wang G, Xu H, et al. MicroRNA-335 and its target Rock1 synergistically influence tumor progression and prognosis in osteosarcoma. Oncol Lett. 2017;13(5):3057–65.CrossRefPubMedPubMedCentral
113.
Hu C, Zhou H, Liu Y, Huang J, Liu W, Zhang Q, et al. ROCK1 promotes migration and invasion of non-small-cell lung cancer cells through the PTEN/PI3K/FAK pathway. Int J Oncol. 2019;55(4):833–44.PubMedPubMedCentral
114.
115.
Li X, Xiao R, Tembo K, Hao L, Xiong M, Pan S, et al. PEG10 promotes human breast cancer cell proliferation, migration and invasion. Int J Oncol. 2016;48(5):1933–42.CrossRefPubMed
116.
Ding F, Jiang K, Sheng Y, Li C, Zhu H. LncRNA MIR7-3HG executes a positive role in retinoblastoma progression via modulating miR-27a-3p/PEG10 axis. Exp Eye Res. 2020;193: 107960.CrossRefPubMed
117.
Akamatsu S, Wyatt AW, Lin D, Lysakowski S, Zhang F, Kim S, et al. The placental gene PEG10 promotes progression of neuroendocrine prostate cancer. Cell Rep. 2015;12(6):922–36.CrossRefPubMed
118.
Lu J, Tang L, Xu Y, Ge K, Huang J, Gu M, et al. Mir-1287 suppresses the proliferation, invasion, and migration in hepatocellular carcinoma by targeting PIK3R3. J Cell Biochem. 2018;119(11):9229–38.CrossRefPubMed
119.
Schwarzenbacher D, Klec C, Pasculli B, Cerk S, Rinner B, Karbiener M, et al. MiR-1287-5p inhibits triple negative breast cancer growth by interaction with phosphoinositide 3-kinase CB, thereby sensitizing cells for PI3Kinase inhibitors. Breast Cancer Res. 2019;21(1):20.CrossRefPubMedPubMedCentral
120.
Li Y, Hu J, Li L, Cai S, Zhang H, Zhu X, et al. Upregulated circular RNA circ_0016760 indicates unfavorable prognosis in NSCLC and promotes cell progression through miR-1287/GAGE1 axis. Biochem Biophys Res Commun. 2018;503(3):2089–94.CrossRefPubMed
121.
Ji F, Du R, Chen T, Zhang M, Zhu Y, Luo X, et al. Circular RNA circSLC26A4 accelerates cervical cancer progression via miR-1287-5p/HOXA7 axis. Mol Ther Nucleic Acids. 2020;19:413–20.CrossRefPubMed
122.
Wang H, Shi J, Luo Y, Liao Q, Niu Y, Zhang F, et al. LIM and SH3 Protein 1 induces TGFβ-mediated epithelial-mesenchymal transition in human colorectal cancer by regulating S100A4 expression. Clin Cancer Res. 2014;20(22):5835–47.CrossRefPubMed
123.
Wang B, Feng P, Xiao Z, Ren E-C. LIM and SH3 protein 1 (Lasp1) is a novel p53 transcriptional target involved in hepatocellular carcinoma. J Hepatol. 2009;50(3):528–37.CrossRefPubMed
124.
Zhang J, Fan J. Prazosin inhibits the proliferation, migration and invasion, but promotes the apoptosis of U251 and U87 cells via the PI3K/AKT/mTOR signaling pathway. Exp Ther Med. 2020;20(2):1145–52.CrossRefPubMedPubMedCentral
125.
Qin M, Liu G, Huo X, Tao X, Sun X, Ge Z, et al. Hsa_circ_0001649: a circular RNA and potential novel biomarker for hepatocellular carcinoma. Cancer Biomark. 2016;16:161–9.CrossRefPubMed
126.
Kim HI, Schultz CR, Buras AL, Friedman E, Fedorko A, Seamon L, et al. Ornithine decarboxylase as a therapeutic target for endometrial cancer. PLoS ONE. 2017;12(12): e0189044.CrossRefPubMedPubMedCentral
127.
Choi Y, Oh ST, Won M-A, Choi KM, Ko MJ, Seo D, et al. Targeting ODC1 inhibits tumor growth through reduction of lipid metabolism in human hepatocellular carcinoma. Biochem Biophys Res Commun. 2016;478(4):1674–81.CrossRefPubMed
128.
129.
Hogarty MD, Norris MD, Davis K, Liu X, Evageliou NF, Hayes CS, et al. ODC1 is a critical determinant of MYCN oncogenesis and a therapeutic target in neuroblastoma. Can Res. 2008;68(23):9735–45.CrossRef
130.
Zhou Z, Lin Z, He Y, Pang X, Wang Y, Ponnusamy M, et al. The long noncoding RNA D63785 regulates chemotherapy sensitivity in human gastric cancer by targeting miR-422a. Mol Ther Nucleic Acids. 2018;12:405–19.CrossRefPubMedPubMedCentral
131.
Li P, Li Q, Zhang Y, Sun S, Liu S, Lu Z. MiR-422a targets MAPKK6 and regulates cell growth and apoptosis in colorectal cancer cells. Biomed Pharmacother. 2018;104:832–40.CrossRefPubMed
132.
Zou Y, Chen Y, Yao S, Deng G, Liu D, Yuan X, et al. MiR-422a weakened breast cancer stem cells properties by targeting PLP2. Cancer Biol Ther. 2018;19(5):436–44.CrossRefPubMedPubMedCentral
133.
Bai C, Sen P, Hofmann K, Ma L, Goebl M, Harper JW, et al. SKP1 connects cell cycle regulators to the ubiquitin proteolysis machinery through a novel motif, the F-box. Cell. 1996;86(2):263–74.CrossRefPubMed
134.
Craig KL, Tyers M. The F-box: a new motif for ubiquitin dependent proteolysis in cell cycle regulation and signal transduction. Prog Biophys Mol Biol. 1999;72(3):299–328.CrossRefPubMed
135.
136.
Peng L, Sang H, Wei S, Li Y, Jin D, Zhu X, et al. circCUL2 regulates gastric cancer malignant transformation and cisplatin resistance by modulating autophagy activation via miR-142-3p/ROCK2. Mol Cancer. 2020;19(1):156.CrossRefPubMedPubMedCentral
137.
Pusapati RV, Weaks RL, Rounbehler RJ, McArthur MJ, Johnson DG. E2F2 suppresses Myc-induced proliferation and tumorigenesis. Mol Carcinog. 2010;49(2):152–6.CrossRefPubMedPubMedCentral
138.
Qi Y, Zhang B, Wang J, Yao M. Upregulation of circular RNA hsa_circ_0007534 predicts unfavorable prognosis for NSCLC and exerts oncogenic properties in vitro and in vivo. Gene. 2018;676:79–85.CrossRefPubMed
139.
Ding D, Wang D, Shu Z. Hsa_circ_0007534 knockdown represses the development of colorectal cancer cells through regulating miR-613/SLC25A22 axis. Eur Rev Med Pharmacol Sci. 2020;24(6):3004–22.PubMed
140.
Rong X, Gao W, Yang X, Guo J. Downregulation of hsa_circ_0007534 restricts the proliferation and invasion of cervical cancer through regulating miR-498/BMI-1 signaling. Life Sci. 2019;235: 116785.CrossRefPubMed
141.
Chai Y, Xiao J, Du Y, Luo Z, Lei J, Zhang S, et al. A novel treatment approach for retinoblastoma by targeting epithelial growth factor receptor expression with a shRNA lentiviral system. Iran J Basic Med Sci. 2017;20(7):739–44.PubMedPubMedCentral
142.
Ecke TH, Stier K, Weickmann S, Zhao Z, Buckendahl L, Stephan C, et al. miR-199a-3p and miR-214-3p improve the overall survival prediction of muscle-invasive bladder cancer patients after radical cystectomy. Cancer Med. 2017;6(10):2252–62.CrossRefPubMedPubMedCentral
143.
Fang Y-Y, Tan M-R, Zhou J, Liang L, Liu X-Y, Zhao K, et al. miR-214-3p inhibits epithelial-to-mesenchymal transition and metastasis of endometrial cancer cells by targeting TWIST1. Onco Targets Ther. 2019;12:9449–58.CrossRefPubMedPubMedCentral
144.
Qin C, Yang X, Jin G, Zhan Z. LncRNA TSLNC8 inhibits proliferation of breast cancer cell through the miR-214-3p/FOXP2 axis. Eur Rev Med Pharmacol Sci. 2019;23(19):8440–8.PubMed
145.
Yang L, Zhang L, Lu L, Wang Y. miR-214-3p regulates multi-drug resistance and apoptosis in retinoblastoma cells by targeting ABCB1 and XIAP. Onco Targets Ther. 2020;13:803–11.CrossRefPubMedPubMedCentral
146.
Song L, Xiao Y. Downregulation of hsa_circ_0007534 suppresses breast cancer cell proliferation and invasion by targeting miR-593/MUC19 signal pathway. Biochem Biophys Res Commun. 2018;503(4):2603–10.CrossRefPubMed
147.
Sun X-H, Wang Y-T, Li G-F, Zhang N, Fan L. Serum-derived three-circRNA signature as a diagnostic biomarker for hepatocellular carcinoma. Cancer Cell Int. 2020;20(1):226.CrossRefPubMedPubMedCentral
148.
Zhao SY, Wang J, Ouyang SB, Huang ZK, Liao L. Salivary circular RNAs Hsa_Circ_0001874 and Hsa_Circ_0001971 as novel biomarkers for the diagnosis of oral squamous cell carcinoma. Cell Physiol Biochem. 2018;47(6):2511–21.CrossRefPubMed
Metadata
Title
The functional role of circular RNAs in the pathogenesis of retinoblastoma: a new potential biomarker and therapeutic target?
Authors
Mohsen Karami Fath
Sasan Pourbagher Benam
Niloofar Kouhi Esfahani
Negar Shahkarami
Shahriyar Shafa
Hossein Bagheri
Seyyed-Ghavam Shafagh
Zahra Payandeh
Ghasem Barati
Publication date
31-03-2023
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology / Issue 8/2023
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-023-03144-2

Other articles of this Issue 8/2023

Clinical and Translational Oncology 8/2023 Go to the issue

REVIEW ARTICLE

Chimeric antigen receptor T cells therapy in solid tumors

RESEARCH ARTICLE

Validation of a prognostic model for predicting larynx preservation outcome (TALK score) in a Southern European population

RESEARCH ARTICLE

SUV39H1 is a prognosis and immune microenvironment-related biomarker in diffuse large B-cell lymphoma

RESEARCH ARTICLE

PD-L1/PD-1 blockage enhanced the cytotoxicity of natural killer cell on the non-small cell lung cancer (NSCLC) by granzyme B secretion

RESEARCH ARTICLE

Comparison of the predictive value of pathological response at primary tumor and lymph node status after neoadjuvant chemotherapy in locally advanced gastric cancer

RESEARCH ARTICLE

Clinical characteristics of pediatric allogeneic hematopoietic stem cell transplantation-associated thrombotic microangiopathy (TA-TMA): a retrospective single-center analysis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits